Related Experiment Video
Updated: Jun 14, 2026

Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide
Published on: May 12, 2023
The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design
Maaike H Oosterveer1, Aldo Grefhorst, Albert K Groen
1Department of Pediatrics, Center for Liver Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. m.h.oosterveer@med.umcg.nl
Abstract:
Liver X receptor (LXR) α and β are nuclear receptors that control cellular metabolism. LXRs modulate the expression of genes involved in cholesterol and lipid metabolism in response to changes in cellular cholesterol status. Because of their involvement in cholesterol homeostasis, LXRs have emerged as promising drug targets for anti-atherosclerotic therapies. In rodents, synthetic LXR agonists promote cellular cholesterol efflux, transport and excretion. As a result, the progression of atherosclerosis is halted. However, pharmacological LXR activation also induces hepatic steatosis and promotes the secretion of atherogenic triacylglycerol-rich VLDL particles by the liver, complicating the clinical application of LXR agonists. The more recently emerged roles of LXRs in fat tissue, pituitary and brain may have implications for treatment of obesity and Alzheimer disease. In addition to the improvements in atherosclerosis, LXR activation exerts beneficial effects on glucose control in mouse models of type 2 diabetes. Future therapeutic strategies aiming to exert beneficial effects on cholesterol and glucose homeostasis, while circumventing the undesired effects on hepatic lipid metabolism, should target specific LXR-mediated processes. Therefore, tissue and/or isotype-specific effects of LXR action need to be established. The consequences of combinatorial drug approaches and the identification of the co-regulatory networks involved in the LXR-mediated control of particular genes may contribute to development of novel LXR agonists. Finally, pathway analyses of LXR actions provide tools to evaluate and optimize the effectiveness of novel therapeutic strategies to prevent and/or treat metabolic diseases.
Insights
Liver X receptors (LXRs) regulate metabolism and show promise for treating atherosclerosis and diabetes. However, side effects like fatty liver necessitate targeted therapies for safe clinical use.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Liver X receptors (LXRs) α and β are nuclear receptors crucial for regulating cellular cholesterol and lipid metabolism.
- LXRs respond to cellular cholesterol levels, making them key targets for treating metabolic diseases like atherosclerosis.
- Previous studies in rodents show LXR agonists can halt atherosclerosis but cause adverse effects like hepatic steatosis.
Purpose of the Study:
- To explore the multifaceted roles of LXRs beyond cholesterol homeostasis, including implications for obesity, Alzheimer's disease, and type 2 diabetes.
- To identify strategies for developing novel LXR agonists that maximize therapeutic benefits while minimizing adverse effects.
- To establish tissue- and isotype-specific effects of LXR action for targeted therapeutic development.
Main Methods:
- Review of existing literature on LXR function and pharmacological activation.
- Analysis of LXR's role in cholesterol efflux, transport, and excretion in preclinical models.
- Investigation of LXR's impact on hepatic lipid metabolism, glucose control, and other physiological processes.
Main Results:
- LXR activation effectively promotes cholesterol efflux and halts atherosclerosis progression in rodents.
- Pharmacological LXR activation can lead to undesirable hepatic steatosis and increased secretion of atherogenic VLDL particles.
- Emerging evidence suggests LXRs play roles in fat tissue, pituitary, and brain, with potential therapeutic implications for obesity and Alzheimer's disease.
- LXR activation demonstrates beneficial effects on glucose control in mouse models of type 2 diabetes.
Conclusions:
- Targeting specific LXR-mediated processes is essential for developing effective therapies for metabolic diseases.
- Understanding tissue- and isotype-specific LXR actions is critical for circumventing adverse effects.
- Combinatorial drug approaches and identification of co-regulatory networks can lead to novel LXR agonists with improved therapeutic profiles.
- Pathway analyses of LXR actions offer valuable tools for optimizing novel therapeutic strategies for metabolic disorders.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Cholesterol: Significance and Regulation
Considering cholesterol and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Signal Transduction: Overview
Typically, signal transduction involves three...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
